Analyses of antibiotic treatment failures are undertaken in different ways in various clinical trials . Regulatory agencies have revised the requirements that pharmaceutieal manufacturers use to determine microbiologic outcomes in clinical trials. A familiarity with differences in study design and the criteria used to establish outcomes can help otolaryngologists look at studies more critically and understand howand why a particular treatment in a specific patient or group of patients was considered a failure.
Classification criteria for success and failure
In clinical studies conducted up to 10 years ago, simple improvement in signs and symptoms was often sufficient to qualify a regimen as a clinical success. In today ' s environment, however, mere impravement represents a treatment failure; for a regimen to be classified as a clinical success, it is necessary that all signs and symptoms be completely resoIved.
Similarly, microbiologic success 10 years ago was declared when there was only a reduction in the amount of a particular pathogen rather than an eradication. In other words, the patient was almost cured , and this was sufficient to qualify as a success. But again, in today's environment, the presence of any amount of pathogen represents a treatment failure. Of course, treatment is an obvious microbiologic failure if the pretherapy pathogen persists, but it is also considered to be a failure ifthe patient stiil has signs or symptoms because a dijferentpathogen is present. In such a case, the presence of the new pathogen does not represent persistence; rather, it represents a superinfection or reinfection, depending on when the new pathogen appeared.
Eradication of the offending pathogen can be either documented or presumed. Eradication is documented by taking a microbiologic sample of the cured tissue. When the act of obtaining such a sample is not desirable or feasible, and if clinical signs and symptoms are absent, eradication can be presumed. For example, in the evaluation of patients who have been treated for acute otitis media with otorrhea through tympanostomy tubes (AOMT), there is no justification for obtaining a post-14· Volume 82 • Suppl 2 therapy specimen from the middle ear cavity when no otorrhea is present. Essentially, the otolaryngologist would be attempting to sample something that is not there . Therefore, in the absence of clinical signs or symptoms, microbiologic cure can be reliably presumed.
Timing of outcome assessment
Another function that has been revised is the timing of outcomes assessments. Ten years ago, clinical and microbiologic efficacy was assessed as soon as the patient completed the course of therapy. Today we assess outcomes at the test-of-cure visit, which usually takes place 3 to 7 days after the completion of therapy . This additional time allows the otolaryngologist to deteet any re-emergence of pathogens that were not eradicated. In clinical trials, of course, a physician can declare a treatment failure at any time if the patient is not responding.
Defining a pathogen according to growth rate
Another newelement in assessing microbiologic outcomes in otic studies concerns the definition of what constitutes a pathogen. With some exceptions, Dohar et al contend that a pathogen is defined as an organism that is recovered with at least a 2+ growth index.' Two notable exceptions pertain to Hemophilus influenzae and Streptococcus pneumoniae; any presence of these organismseven if it is only with a 1+ growth index-is sufficient to qualify as pathogenic. Conversely, Dohar et al list approximately 20 bacterial species that are never considered pathogenic, even when they are recovered with a 3+ or 4+ growth index. But the major organisms seen in AOMT are considered pathogenic if they are recovered with a 2+ growth index . The amount of growth is usually measured 1 or 2 days after the specimen is placed on the plate in the laboratory. In some clinical studies, plates have been incubated for as long as 5 days in an attempt to recover ev erything that might be present.
Microbiologic recovery vs DNA detection
In some ophthalmology studies and in an AOMT study that has just gotten under way, a new protocol was implemented that involves not just the recovery of bacteria, but its dete etian by polymerase ehain reaetion (PCR) methods. With DNA-based teehnology, baeteria ean be deteeted regardless of how little is present. For deteetion purposes, quantity is irrelevant; it is the presenee that matterso Baeterial deteetion has shed quite a bit of light on organisms that have not been reeoverable even though they are perfeetly respeetable aerobes or anaerobes. Of eourse, the faet that an organism ean be reeovered does not mean it is pathogenie. This has some bearing in AOMT, beeause the pathogens that are reeovered are those that grow very easil y. This does not mean that these organisms are the only ones present, but AOMT has typieally been defined by the presenee of organisms that are the easiest to isolate.
One interesting discovery that we made by using DNAbased deteetion was thatAlloiococcus otitidis is extremely common in healthy ear eanals; only Turicella otitidis and Coryneform baeteria are more common. We have found A otitidis in approximately 40% of healthy ear eanals. We also learned that A otitidis is not usually reeoverable unIess it is ineubated for 5 days, and even then we find only a "haze" of growth. It grows very slowly. Our findings were confirmed by Frank et al, who studied healthy ears by PCR.2 They found that A otitidis and T otitidis were the most common organisms.
On the other hand, A otitidis has been elassified as pathogenie by Bosley et al in Finland.' They diseoveredA otitidis by DNA-based teehnology in patients with middle ear infeetions. They tried repeatedly to reeover A otitidis from middle ear effusions by standard mierobiologie means but were unable to do so. Nevertheless, they argued that it is indeed pathogenie, based on their DNAdeteetion studies . Therefore, the eriteria used to classify an organism as pathogenie or not varies from study to study and often depends on the investigators' ability to reeover it and on how weIl it grows.
Some seientists argue that an organism is not pathogenie if it does not grow weIl. However, in our studies of eonjunetivitis in the United States , we missed probably 20% of cases of H influen zae and S pneumoniae infeetion simply beeause we were unable to reeover them . And these are two well-known pathogens. Whether or not organisms are reeovered and identified as pathogens is a funetion of mierobiologie technique.
The reasons for our failure to reeover H influen zae and S pneumoniae are not clear eut. It might have been that these organisms were not present in abundanee. AIso, they are both rather fastidious and sometimes diffieult to reeover. DNA-based deteetion, on the other hand, is much more sensitive than stand ard mierobiologie teehniques. It ean deteet as few as five eelIs on a speeimen swab. For example, Gemella hemolysans is a strepoeeoeus-like organism found in patients with eonjunetivitis. Although it has never been reeovered by standard mierobiologie teehniques , DNA teehnology deteeted 30 cases of it.
Similarly, we have eolleeted 12,000 baeterial isolates during the past 4 years, and standard mierobiology has reeovered only two cases of Coryn ebacterium tuberculostearicum-one from an infeeted ear and one from an infeeted eye. But when we used DNA teehnology on the same speeimens, we deteeted more than 30 cases. For whatever reason-perhaps this organism has some unusual growth requirement-we generally have not been able to reeover C tuberculostearicum, even though it is eertainly present.
Finally, Rhizobium radiobacter is another organism we have reeovered only oeeasionally from swabs but have deteeted quite often by DNA-based teehnology. It is worth noting that DNA analysis rarely deteeted G hemolysans, C tuberculostearicum, and R radiobacter at the test-of-cure visit. They were deteeted primarily at the pretreatment visit, whieh tells us that the antibiotie is eradicating them.
Simonsieila spp are gram-negative organisms that resemble Neissaia spp, and they are found in many eonjunetivitis patients. They were first deseribed 100 years ago, but they are rarely reported today beeause they are rarely reeovered. We reeover Propionibacterium acnes in patients with ear and eye infeetions only oeeasionally; DNA-based teehnology deteets it at least 50 times more often.
As suggested earlier, one problem with DNA-based deteetion is that it eannot identify the relative quantity of one speeies versus another in the same sample. The teehnology ean identify whieh organisms are present, but it eannot distinguish the proportions of those organisms. Nevertheless, the ability to deteet multiple baeteria in a single speeimen is useful. We now routinely look for all Chlamydia spp in a specimen . In a reeent conjunetivitis study, we reeovered Chlamydia felis from two patients. The literature eontains onlyone ease ofeonjunctivitis that was eaused by C felis, but with DNA-based teehnology, we have already identified two more.
Pathogens implicated in treatment failures
Data on specifie mierobiologic failure rates have been obtained in two phase III studies of ciprofloxacin/dexamethasone otie solution; one study was conducted in patients with acute otitis externa (AOE) and one in patients with AOMT (see page 2). All outeomes were measured by standard microbiologie techniques, and all failures were confirmed by DNA fingerprinting. Treatment successes werejudged eonservatively. Forexample, a treatment was elassified as a failure if any sign of residual infeetion remained in a patient who did not undergo follow-up testing to determine whether the residual baeteria represented the original pathogen or a neworganism. Such a circum stance was con sidered to represent a presumed failure . The assumption was that the remaining bacteria represented the original pathogen . Thi s protocol was somewhat misleading because in most cases when residu al infecti on was identified, the bacteria were found to be new . All evaluations were conducted at the test-of-cure visit.
In AOE , treatment eradicated 38 of 42 cases (90.5%) of Staphylococcus aureus infection; of the four treatment failures (9.5%), one was documented and three were presumed. In cases of Pseudomonas aeruginosa infecti on, treatment eradicated the pathogen in 223 of 232 cases (96.1 %); of the nine failure s (3.9%), five were documented and four were presum ed.
In the AOMT study , all failure s were documented; none was presum ed. Ciprofloxacin/dexamethasone treatment failed in two of 26 (7.7 %) H influ enzae infections, in six of 44 (13.6%) S pn eumoniae infections, in three of 53 (5.7%) S aureus infections, and in one of 48 (2.1%) P ae ruginosa infections. As was the case with the AOE study, none of the pathogens was resistant to ciprafloxacin prior to therapy , and none became resistant to ciproflox acin during therapy .
Antibiotic resistance
The question is often asked as to whether the incre ase in antibiotic-resistant isolates has resulted in a corresponding increase in treatm ent failures. Thus far, no clear-cut evidence has been found that resistant strains lead to more c1inical failure s. Stud ies of the lower respiratory tract have yielded conflicting findings. Pichichera et al studied a group of children with recurrent and persistent otiti s media and suggested that resistance is not a factor in treatment failures.' Some of these chronic infect ion s were caused by resist ant organi sms, but many were caused by susceptible organisms.
In a recent study in Ind ia (unpublished), microbiologic spec imen s were collected from the eyes of healthy subjects in the community and the eyes of ophthalmologists them selve s. The ophthalmologists, who had aecess to free antibiotics, had many more resistant organisms in their healthy flora than did those from poorer areas of the country where there was no aecess to antibiotics. However, the ophth almologist s did not have a greater incidenc e of infection. Their greater incidenee of resistant strains did not result in a higher rate of disease.
Finall y, Watu rangi et al studied a group of antibioticnaive lizards from remote areas of Indonesia and recovered 23 strains of Escherichia eoli, 70 % of which were resistan t to tetracycline.' In fact, the lizards had the same resistance gene s as do hum ans. benefit of PCR lies in its ability to deteet pathogens in place s where they are not usually present. PCR would presum ably yield a positi ve for an organism even ifthere were only one dead organism in the specimen. Therefore, I do not see how it is worthwhile to look for these organisms in mucosal areas that are in pro ximit y to the skin or the oral cavit y, because we would expect them to be there . If you examined a series of specimens taken from tears, for example, I suspect that they would all be PCRpositive, at some point or another, for every orga nism that' s present in the air.
Discussion
Second, we typically diagnose otitis and sinusitis on the basis of the presence or abse nce of organisms. But that' s probably a naive assumption, because healthy people can also harbor pathogens in low numbers. Therefore, we should probably rethink how we define disease in the middle eal' , in the nose, in the eye , etc. Perhaps we shouId discard our black-and-white, all-o r-nothin g way ofthinking and consider the relative cont ributions to the inflammatory proce ss of the various amounts of bacteria, viruses, and intrin sie inflammatory mediators. At any rate, the landscape is constantly changing, and PCR is helping us understand that a little better.
Dr. Manning: When you attempt to deteet organisms by PCR , is it true thatyou cari't use a cotton swa b becau se dead bacterial DNA might be present on the swab? Dr. Stroman: No, that ' s not true . Certa inly , swabs do become contaminated, but we control for it. In fact, there is one parti cular bacterium-Delftia acidovorans-that we find quite often on swabs. And swabs supplied by cert ain companies are contaminated by waterborne organisms that are intraduced during manufacturing.
Dr. Manning: At our children ' s hospital in Seattle, about 50 % of neck absce sses grow nothing on routine culture. Our first step is to perform PCR for Bartonella henselae-that is, cat scratch-if the standard culture is steriIe. If the B henselae PCR is negative, our pathologist will perform further PCR testin g to look for other organisms. For example , we recently diagnosed a case of Legion ella micdadei infection , which had never been known to cause an abscess. But we supported this diagnosis with acute and con valescent titers on serology.
Prof. Hawke: I think DNA detection is an excitin g devel opment. However, I wonder how accurate it will be because it identi fies both dead and live bacteri a that might not necessarily be the cau se of the infection .
Dr. Stroman: Absolutely. However, I should mention that even though DNA-based detection does not distingui sh between dead and live organisms, the DNA in dead organi sms degrade s very rapidl y in the liquid environment of an incub ator and in a body with an elevated temperature . So for the most part, we are detecting live org anisms.
Dr. Haynes: There has been some talk about the differ-ence between ob taining a culture sample from a tube or perforation and obtaining it by swabbing the earcanal. We know there are differe nt types ofbacteria at these different sites. Has a study ever been conducted to determine j ust how much of a difference? Dr. Stroman: No . There is too much variation among physicians with respeet to how they collec t culture specimens to allow us to arr ive at valid conclusions . Ifwe were to perform such a study , the res ults would not be applicable to all physicians .
Prof. Hawke: Wit h respeet to ant ibiot ic treatment failures, I wo nder if we cou ld go back to the initia l visit and determine whet her there was anythi ng that could be identifiab le as a contributing factor, such as the presence or absence of a wick, the severity of disease, etc. Are there any clues tha t we might pick up by reviewi ng the findings on the initial eval uation ? .
Dr. Stroman: I do n' t know . We know that some parameters are not risk fac tors, but we do n' t know whic h are .
